These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 30956155)

  • 1. Newborn screening for cystic fibrosis: Is there benefit for everyone?
    Course CW; Hanks R
    Paediatr Respir Rev; 2019 Aug; 31():3-5. PubMed ID: 30956155
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo and in vitro ivacaftor response in cystic fibrosis patients with residual CFTR function: N-of-1 studies.
    McGarry ME; Illek B; Ly NP; Zlock L; Olshansky S; Moreno C; Finkbeiner WE; Nielson DW
    Pediatr Pulmonol; 2017 Apr; 52(4):472-479. PubMed ID: 28068001
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Change in sweat chloride as a clinical end point in cystic fibrosis clinical trials: the ivacaftor experience.
    Durmowicz AG; Witzmann KA; Rosebraugh CJ; Chowdhury BA
    Chest; 2013 Jan; 143(1):14-18. PubMed ID: 23276841
    [TBL] [Abstract][Full Text] [Related]  

  • 4. VX-659-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.
    Davies JC; Moskowitz SM; Brown C; Horsley A; Mall MA; McKone EF; Plant BJ; Prais D; Ramsey BW; Taylor-Cousar JL; Tullis E; Uluer A; McKee CM; Robertson S; Shilling RA; Simard C; Van Goor F; Waltz D; Xuan F; Young T; Rowe SM;
    N Engl J Med; 2018 Oct; 379(17):1599-1611. PubMed ID: 30334693
    [TBL] [Abstract][Full Text] [Related]  

  • 5. VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.
    Keating D; Marigowda G; Burr L; Daines C; Mall MA; McKone EF; Ramsey BW; Rowe SM; Sass LA; Tullis E; McKee CM; Moskowitz SM; Robertson S; Savage J; Simard C; Van Goor F; Waltz D; Xuan F; Young T; Taylor-Cousar JL;
    N Engl J Med; 2018 Oct; 379(17):1612-1620. PubMed ID: 30334692
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phenotype of children with inconclusive cystic fibrosis diagnosis after newborn screening.
    Munck A; Bourmaud A; Bellon G; Picq P; Farrell PM;
    Pediatr Pulmonol; 2020 Apr; 55(4):918-928. PubMed ID: 31916691
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The implications and management of cystic fibrosis screen positive, inconclusive diagnosis patients.
    Krishnananthan T; Pao C
    Paediatr Respir Rev; 2019 Aug; 31():21-24. PubMed ID: 31153793
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2-5 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study.
    Davies JC; Cunningham S; Harris WT; Lapey A; Regelmann WE; Sawicki GS; Southern KW; Robertson S; Green Y; Cooke J; Rosenfeld M;
    Lancet Respir Med; 2016 Feb; 4(2):107-15. PubMed ID: 26803277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CFTR-dependent chloride efflux in cystic fibrosis mononuclear cells is increased by ivacaftor therapy.
    Guerra L; D'Oria S; Favia M; Castellani S; Santostasi T; Polizzi AM; Mariggiò MA; Gallo C; Casavola V; Montemurro P; Leonetti G; Manca A; Conese M
    Pediatr Pulmonol; 2017 Jul; 52(7):900-908. PubMed ID: 28445004
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Measurement of nasal potential difference in young children with an equivocal sweat test following newborn screening for cystic fibrosis.
    Sermet-Gaudelus I; Girodon E; Roussel D; Deneuville E; Bui S; Huet F; Guillot M; Aboutaam R; Renouil M; Munck A; des Georges M; Iron A; Thauvin-Robinet C; Fajac I; Lenoir G; Roussey M; Edelman A
    Thorax; 2010 Jun; 65(6):539-44. PubMed ID: 20522854
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic benefit of ivacaftor in late cystic fibrosis caused by homozygous IVS8-5T CFTR polymorphism.
    Magne F; Durupt S; Nove-Josserand R; Bey-Omar F; Laoust L; Cottin V; Durieu I; Reynaud Q
    J Cyst Fibros; 2017 Jan; 16(1):89-90. PubMed ID: 27810230
    [No Abstract]   [Full Text] [Related]  

  • 12. Ivacaftor and Airway Inflammation in Preschool Children with Cystic Fibrosis.
    McNally P; Butler D; Karpievitch YV; Linnane B; Ranganathan S; Stick SM; Hall GL; Schultz A
    Am J Respir Crit Care Med; 2021 Sep; 204(5):605-608. PubMed ID: 34077699
    [No Abstract]   [Full Text] [Related]  

  • 13. New Therapeutic Approaches to Modulate and Correct Cystic Fibrosis Transmembrane Conductance Regulator.
    Ong T; Ramsey BW
    Pediatr Clin North Am; 2016 Aug; 63(4):751-64. PubMed ID: 27469186
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes of Cystic Fibrosis Screening-Positive Infants With Inconclusive Diagnosis at School Age.
    Gonska T; Keenan K; Au J; Dupuis A; Chilvers MA; Burgess C; Bjornson C; Fairservice L; Brusky J; Kherani T; Jober A; Kosteniuk L; Price A; Itterman J; Morgan L; Mateos-Corral D; Hughes D; Donnelly C; Smith MJ; Iqbal S; Arpin J; Reisman J; Hammel J; van Wylick R; Derynck M; Henderson N; Solomon M; Ratjen F
    Pediatrics; 2021 Dec; 148(6):. PubMed ID: 34814176
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The U.S. Food and Drug Administration's Experience with Ivacaftor in Cystic Fibrosis. Establishing Efficacy Using In Vitro Data in Lieu of a Clinical Trial.
    Durmowicz AG; Lim R; Rogers H; Rosebraugh CJ; Chowdhury BA
    Ann Am Thorac Soc; 2018 Jan; 15(1):1-2. PubMed ID: 29020455
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cystic Fibrosis: The Dawn of a New Therapeutic Era.
    Heltshe SL; Cogen J; Ramos KJ; Goss CH
    Am J Respir Crit Care Med; 2017 Apr; 195(8):979-984. PubMed ID: 27710011
    [No Abstract]   [Full Text] [Related]  

  • 17. Diagnostic dilemmas resulting from the immunoreactive trypsinogen/DNA cystic fibrosis newborn screening algorithm.
    Parad RB; Comeau AM
    J Pediatr; 2005 Sep; 147(3 Suppl):S78-82. PubMed ID: 16202789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ivacaftor withdrawal syndrome in cystic fibrosis patients with the G551D mutation.
    Trimble AT; Donaldson SH
    J Cyst Fibros; 2018 Mar; 17(2):e13-e16. PubMed ID: 29079142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cystic fibrosis: What's new in South Africa in 2019.
    Zampoli On Behalf Of The Msac M
    S Afr Med J; 2018 Dec; 109(1):16-19. PubMed ID: 30606298
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Refining the continuum of CFTR-associated disorders in the era of newborn screening.
    Levy H; Nugent M; Schneck K; Stachiw-Hietpas D; Laxova A; Lakser O; Rock M; Dahmer MK; Biller J; Nasr SZ; Baker M; McColley SA; Simpson P; Farrell PM
    Clin Genet; 2016 May; 89(5):539-49. PubMed ID: 26671754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.